Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups.
Adequate balance sheet with proven track record.
Share Price & News
How has Oncodesign Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALONC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ALONC exceeded the French Biotechs industry which returned -13.8% over the past year.
Return vs Market: ALONC exceeded the French Market which returned -7.9% over the past year.
Price Volatility Vs. Market
How volatile is Oncodesign Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWith A Return On Equity Of 13%, Has Oncodesign Société Anonyme's (EPA:ALONC) Management Done Well?
3 months ago | Simply Wall StIs Oncodesign Société Anonyme (EPA:ALONC) A Risky Investment?
4 months ago | Simply Wall StIf You Had Bought Oncodesign Société Anonyme (EPA:ALONC) Shares A Year Ago You'd Have Made 49%
Is Oncodesign Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ALONC (€12.15) is trading above our estimate of fair value (€1.41)
Significantly Below Fair Value: ALONC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ALONC is poor value based on its PE Ratio (81.8x) compared to the Biotechs industry average (33.5x).
PE vs Market: ALONC is poor value based on its PE Ratio (81.8x) compared to the French market (14.6x).
Price to Earnings Growth Ratio
PEG Ratio: ALONC is poor value based on its PEG Ratio (10.1x)
Price to Book Ratio
PB vs Industry: ALONC is overvalued based on its PB Ratio (10.3x) compared to the FR Biotechs industry average (3x).
How is Oncodesign Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALONC's forecast earnings growth (8.1% per year) is above the savings rate (0.6%).
Earnings vs Market: ALONC's earnings (8.1% per year) are forecast to grow slower than the French market (13% per year).
High Growth Earnings: ALONC's earnings are forecast to grow, but not significantly.
Revenue vs Market: ALONC's revenue (4.6% per year) is forecast to grow faster than the French market (3.9% per year).
High Growth Revenue: ALONC's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALONC's Return on Equity is forecast to be high in 3 years time
How has Oncodesign Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALONC has high quality earnings.
Growing Profit Margin: ALONC became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ALONC has become profitable over the past 5 years, growing earnings by -7.9% per year.
Accelerating Growth: ALONC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ALONC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: ALONC's Return on Equity (20.6%) is considered high.
How is Oncodesign Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: ALONC's short term assets (€27.3M) exceed its short term liabilities (€19.1M).
Long Term Liabilities: ALONC's short term assets (€27.3M) exceed its long term liabilities (€16.6M).
Debt to Equity History and Analysis
Debt Level: ALONC's debt to equity ratio (63.1%) is considered high.
Reducing Debt: ALONC's debt to equity ratio has increased from 1.9% to 63.1% over the past 5 years.
Debt Coverage: ALONC's debt is well covered by operating cash flow (113.6%).
Interest Coverage: ALONC's interest payments on its debt are well covered by EBIT (3.3x coverage).
What is Oncodesign Société Anonyme's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALONC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALONC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALONC's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Philippe Genne, Ph.D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010.
|Chief Financial & Administrative Officer||2.08yrs||no data||no data|
|Chief Scientific Officer||no data||no data||no data|
|Deputy Managing Director||no data||€24.34k||no data|
|Member of Executive Board||12.33yrs||no data||no data|
|Member of Executive Board||12.33yrs||no data||no data|
|Chief of Business Development & Marketing||2.75yrs||no data||no data|
|Head of Human Resources||no data||no data||no data|
|Head of the Experimentation Division||no data||no data||no data|
|Head of the Discovery Division||no data||no data||no data|
Experienced Management: ALONC's management team is seasoned and experienced (10 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Oncodesign Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Oncodesign Société Anonyme
- Ticker: ALONC
- Exchange: ENXTPA
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €82.633m
- Shares outstanding: 6.80m
- Website: https://www.oncodesign.com
Number of Employees
- Oncodesign Société Anonyme
- 20 rue Jean Mazen
- B.P. 27627
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALONC||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Apr 2014|
Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services for proof of concept stage; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company is also involved in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Further, the company is involved in the artificial intelligence business that support development of the drug discovery of the future and halve research and development times for drug candidates. It has a strategic partnership with Servier for the research and development of drug candidates for Parkinson’s disease; and HitGen Inc. for the identification and progression of new chemical entities. The company was founded in 1995 and is headquartered in Dijon, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/30 00:09|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.